Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 17/20 | 1.00 |
| ▸ | MMP3 | P08254 | 17/20 | 1.00 |
| ▸ | MMP2 | P08253 | 16/20 | 1.00 |
| ▸ | MMP9 | P14780 | 12/20 | 1.00 |
| ▸ | MMP8 | P22894 | 5/20 | 1.00 |
| ▸ | MMP14 | P50281 | 4/20 | 1.00 |
| ▸ | MMP13 | P45452 | 3/20 | 1.00 |
| ▸ | ADAM17 | P78536 | 3/20 | 1.00 |
| ▸ | MMP7 | P09237 | 6/20 | 0.66 |
| ▸ | TNF | P01375 | 2/20 | 0.59 |
| ▸ | MMP20 | O60882 | 1/20 | 0.59 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.59 |
| ▸ | MMP10 | P09238 | 1/20 | 0.59 |
| ▸ | MMP12 | P39900 | 1/20 | 0.59 |
| ▸ | MMP15 | P51511 | 1/20 | 0.59 |
| ▸ | MMP16 | P51512 | 1/20 | 0.59 |
| ▸ | MMP25 | Q9NPA2 | 1/20 | 0.59 |
| ▸ | MMP26 | Q9NRE1 | 1/20 | 0.59 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.59 |
| ▸ | MMP24 | Q9Y5R2 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ro-319790 SCHEMBL8188276 | 1.00 | MMP1 (1.00) | MMP1MMP3MMP2MMP9MMP8 | |
| Ro-319790 SCHEMBL8189171 | 1.00 | MMP1 (1.00) | MMP1MMP3MMP2MMP9MMP8 | |
| Ro-319790 SCHEMBL31060724 | 1.00 | MMP1 (1.00) | MMP1MMP3MMP2MMP9MMP8 | |
| Ro-319790 SCHEMBL5491595 | 1.00 | MMP1 (1.00) | MMP1MMP3MMP2MMP9MMP8 | |
| Ro-319790 SCHEMBL4634066 | 1.00 | MMP1 (1.00) | MMP1MMP3MMP2MMP9MMP8 | |
| Ro-319790 SCHEMBL5494052 | 1.00 | MMP1 (1.00) | MMP1MMP3MMP2MMP9MMP8 | |
| SCHEMBL4633112 | 0.85 | MMP3 (0.74) | MMP1MMP3MMP2MMP9MMP8 | |
| SCHEMBL5088865 | 0.85 | MMP3 (0.74) | MMP1MMP3MMP2MMP9MMP8 | |
| SCHEMBL8872686 | 0.83 | MMP2 (0.76) | MMP1MMP3MMP2MMP9MMP8 | |
| SCHEMBL4818599 | 0.83 | MMP3 (0.82) | MMP1MMP3MMP2MMP9MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070049518-A1 | Novel method of treatment of inflammatory skin conditions | SERENTIS LIMITED (GB) | 2007-03-01 | — | — | US | claimed |
| US-20040122011-A1 | Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy | PHARMACIA CORPORATION | 2004-06-24 | — | — | US | claimed |
| EP-0497192-A2 | Amino acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1992-08-05 | — | — | EP | claimed |
| EP-3964242-B1 | SURGICAL STAPLER WITH END EFFECTOR COATING | CILAG GMBH INT (CH) | 2026-02-18 | — | — | EP | disclosed |
| US-11992216-B2 | Surgical stapler with end effector coating | CILAG GMBH INTERNATIONAL (CH) | 2024-05-28 | — | — | US | disclosed |
| CN-117050961-A | Leucine dehydrogenase mutant, genetically engineered bacterium containing leucine dehydrogenase mutant and application of genetically engineered bacterium | 弈柯莱生物科技(集团)股份有限公司 | 2023-11-14 | — | — | CN | disclosed |
| US-11666335-B2 | Surgical stapler with end effector coating | CILAG GMBH INTERNATIONAL (CH) | 2023-06-06 | — | — | US | disclosed |
| US-20230071644-A1 | SURGICAL STAPLER WITH END EFFECTOR COATING | ETHICON LLC (US) | 2023-03-09 | — | — | US | disclosed |
| CN-111032104-B | Surgical stapler with end effector coating | 爱惜康有限责任公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-110740763-B | Surgical fastener device for preventing degradation of ECM | 爱惜康有限责任公司 | 2022-08-09 | — | — | CN | disclosed |
| CN-110769866-B | Surgical stapler with controlled healing | 爱惜康有限责任公司 | 2022-07-29 | — | — | CN | disclosed |
| CN-110740764-B | Surgical fasteners with broad spectrum MMP inhibitors | 爱惜康有限责任公司 | 2022-05-27 | — | — | CN | disclosed |
| EP-3964242-A1 | SURGICAL STAPLER WITH END EFFECTOR COATING | Cilag GmbH International (CH) | 2022-03-09 | — | — | EP | disclosed |
| US-20120135959-A1 | Metalloprotein inhibitors containing nitrogen based ligands | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2012-05-31 | — | — | US | disclosed |
| WO-2011011181-A1 | PHARMACOLOGICAL CHAPERONES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | AMICUS THERAPEUTICS, INC. (US) | 2011-01-27 | — | — | WO | disclosed |
| EP-1931624-A1 | USE OF AN AUREOLYSIN INHIBITOR FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS CHARACTERISED BY COLONISATION WITH STAPHYLOCOCCUS AUREUS | Serentis Limited (GB) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007025999-A1 | USE OF AN AUREOLYSIN INHIBITOR FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS CHARACTERISED BY COLONISATION WITH STAPHYLOCOCCUS AUREUS | SERENTIS LIMITED (GB) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049518-A1 | Novel method of treatment of inflammatory skin conditions | SERENTIS LIMITED (GB) | 2007-03-01 | — | — | US | disclosed |
| EP-0497192-A2 | Amino acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1992-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135959-A1 | Metalloprotein inhibitors containing nitrogen based ligands | MMP8, MMP1, TIMP3 | MMP1 2/4885MMP3 11/4885MMP2 5/4885 |
| US-20040122011-A1 | Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy | PTGES2, PTGS2, PTGIS | MMP1 67/4885MMP3 39/4885MMP2 60/4885 |
| US-20070049518-A1 | Novel method of treatment of inflammatory skin conditions | MMP8, CUTA, MMP1 | MMP1 3/4885MMP3 13/4885MMP2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.